Drug Search Results
More Filters [+]

LML-134

Alternative Names: lml-134, lml134, lml 134
Latest Update: 2019-02-15
Latest Update Note: Clinical Trial Update

Product Description

a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders

Mechanisms of Action: H3 Inverse Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LML-134

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Sleep Disorders, Circadian Rhythm

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CLML134X2201

P2

Terminated

Sleep Disorders, Circadian Rhythm

2018-08-30

LML134

P1

Completed

Healthy Volunteers

2016-02-01

Recent News Events

Date

Type

Title